SCHEMBL4209249

SCHEMBL4209249

CCOC(=O)c1cc(CSC(C)=O)cc(C(=O)OCC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.51
CA12 O43570 3/20 0.51
CA1 P00915 3/20 0.51
CA7 P43166 3/20 0.51
CA9 Q16790 3/20 0.51
CA14 Q9ULX7 3/20 0.51
CYP1A2 P05177 2/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAOA P21397 1/20 0.46
CYP2C19 P33261 2/20 0.45
CYP2C9 P11712 1/20 0.45
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
HSD17B2 P37059 1/20 0.43
KDM4E B2RXH2 1/20 0.41
CYP2D6 P10635 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8302756 0.83 LMNA (0.59) CA2CA12CA1CA7CA9
SCHEMBL4211743 0.83 CA2 (0.55) CA2CA12CA1CA7CA9
SCHEMBL10290650 0.80 CA12 (0.64) CA2CA12CA1CA7CA9
SCHEMBL1664013 0.80 CA12 (0.75) CA2CA12CA1CA7CA9
SCHEMBL9844686 0.80 CYP1A2 (0.54) CA2CA12CA1CA7CA9
SCHEMBL20141409 0.79 CA12 (0.46) CA2CA12CA1CA7CA9
SCHEMBL14341681 0.79 CA12 (0.58) CA2CA12CA1CA7CA9
SCHEMBL341606 0.77 CA12 (0.60) CA2CA12CA1CA7CA9
SCHEMBL3510775 0.76 CA12 (0.64) CA2CA12CA1CA7CA9
SCHEMBL29201195 0.76 CA12 (0.64) CA2CA12CA1CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504420-B2 Compounds which inhibit beta-secretase activity and methods of use COMENTIS, INC. (US) 2009-03-17 US disclosed
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2008-07-24 US disclosed
EP-1871739-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2008-01-02 EP disclosed
US-20070117793-A1 Compounds Which Inhibit Beta-Secretase Activity and Methods of Use ZAPAQ, INC. (US) 2007-05-24 US disclosed
WO-2006110668-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117793-A1 Compounds Which Inhibit Beta-Secretase Activity and Methods of Use BACE1, BACE2, APP CA2 2540/4885CA12 3188/4885CA1 401/4885
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP CA2 3211/4885CA12 3420/4885CA1 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.